Advanced wound care therapies for nonhealing diabetic, venous, and arterial ulcers: a systematic review
N Greer, NA Foman, R MacDonald… - Annals of internal …, 2013 - acpjournals.org
N Greer, NA Foman, R MacDonald, J Dorrian, P Fitzgerald, I Rutks, TJ Wilt
Annals of internal medicine, 2013•acpjournals.orgBackground: Nonhealing ulcers affect patient quality of life and impose a substantial
financial burden on the health care system. Purpose: To systematically evaluate benefits
and harms of advanced wound care therapies for nonhealing diabetic, venous, and arterial
ulcers. Data Sources: MEDLINE (1995 to June 2013), the Cochrane Library, and reference
lists. Study Selection: English-language randomized trials reporting ulcer healing or time to
complete healing in adults with nonhealing ulcers treated with advanced therapies. Data …
financial burden on the health care system. Purpose: To systematically evaluate benefits
and harms of advanced wound care therapies for nonhealing diabetic, venous, and arterial
ulcers. Data Sources: MEDLINE (1995 to June 2013), the Cochrane Library, and reference
lists. Study Selection: English-language randomized trials reporting ulcer healing or time to
complete healing in adults with nonhealing ulcers treated with advanced therapies. Data …
Background
Nonhealing ulcers affect patient quality of life and impose a substantial financial burden on the health care system.
Purpose
To systematically evaluate benefits and harms of advanced wound care therapies for nonhealing diabetic, venous, and arterial ulcers.
Data Sources
MEDLINE (1995 to June 2013), the Cochrane Library, and reference lists.
Study Selection
English-language randomized trials reporting ulcer healing or time to complete healing in adults with nonhealing ulcers treated with advanced therapies.
Data Extraction
Study characteristics, outcomes, adverse events, study quality, and strength of evidence were extracted by trained researchers and confirmed by the principal investigator.
Data Synthesis
For diabetic ulcers, 35 trials (9 therapies) met eligibility criteria. There was moderate-strength evidence for improved healing with a biological skin equivalent (relative risk [RR], 1.58 [95% CI, 1.20 to 2.08]) and negative pressure wound therapy (RR, 1.49 [CI, 1.11 to 2.01]) compared with standard care and low-strength evidence for platelet-derived growth factors and silver cream compared with standard care. For venous ulcers, 20 trials (9 therapies) met eligibility criteria. There was moderate-strength evidence for improved healing with keratinocyte therapy (RR, 1.57 [CI, 1.16 to 2.11]) compared with standard care and low-strength evidence for biological dressing and a biological skin equivalent compared with standard care. One small trial of arterial ulcers reported improved healing with a biological skin equivalent compared with standard care. Overall, strength of evidence was low for ulcer healing and low or insufficient for time to complete healing.
Limitations
Only studies of products approved by the U.S. Food and Drug Administration were reviewed. Studies were predominantly of fair or poor quality. Few trials compared 2 advanced therapies.
Conclusion
Compared with standard care, some advanced wound care therapies may improve the proportion of ulcers healed and reduce time to healing, although evidence is limited.
Primary Funding Source
Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Quality Enhancement Research Initiative.
acpjournals.org